Without a Ribbon
  • About
    • Events
    • Get In Touch
  • Rare Cancer Resources
  • Shop
  • How You Can Help
  • Meet Warriors
  • News
  • Login
  • Register

Select Page

HELP

LEARN

EVENTS

# Resources

Pleomorphic Rhabdomyosarcoma – Symptoms, Treatment & Support

What is Pleomorphic Rhabdomyosarcoma? Pleomorphic rhabdomyosarcoma is a rare and aggressive form of soft tissue cancer. It’s part of the rhabdomyosarcoma family, cancers that develop from skeletal muscle cells. Pleomorphic rhabdomyosarcoma is characterized by...

Malignant Extrarenal Rhabdoid Tumour – Symptoms, Treatment & Support

What is Malignant Extrarenal Rhabdoid Tumour? Malignant extrarenal rhabdoid tumour (MERT) is a rare and highly aggressive cancer that originates outside of the kidneys. Rhabdoid tumours were first identified in the kidneys but can occur in other soft tissues...

Primary Cutaneous Marginal Zone B-cell Lymphoma – Symptoms, Treatment & Support

What is Primary Cutaneous Marginal Zone B-cell Lymphoma? Primary cutaneous marginal zone B-cell lymphoma (PCMZL) is a rare type of low-grade skin lymphoma. It belongs to the group of indolent (slow-growing) non-Hodgkin lymphomas and primarily affects the skin, with a...

Post-Transplant Lymphoproliferative Disorders – Symptoms, Treatment & Support

What are Post-Transplant Lymphoproliferative Disorders (PTLD)? Post-transplant lymphoproliferative disorders (PTLD) are a group of conditions that may occur after an organ or stem cell transplant. These disorders are characterized by an uncontrolled proliferation of...

Plasmacytoma – Symptoms, Treatment & Support

What is Plasmacytoma? Plasmacytoma is a type of cancer that arises from plasma cells, a type of white blood cell that produces antibodies. This condition can present as a single lesion (solitary plasmacytoma) or multiple lesions (multiple myeloma when widespread)....
Older Entries
Next Entries

If you need any help or advice just

Get In Touch

© Without a Ribbon 2019. All rights reserved.Powered by WEB 105 Creative

Stay up to date.

Sign up to our newsletter